Share
.webp)
.webp)
.webp)
.webp)
Jenny R. Robertson
Lexeo Therapeutics, Inc., has announced a series of strategic executive appointments to support the advancement of its pipeline into late-stage clinical development.
“The growing expertise within Lexeo’s leadership has been instrumental in driving some of the most impactful clinical programs, drug approvals, and product launches in rare disease and precision cardiovascular medicine,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “We are excited to leverage the thought leadership and operational experience of our newly appointed executives as we transition our pipeline towards late-stage clinical studies.”
The new appointment include:
Jenny R. Robertson has been named Chief Business and Legal Officer. Ms. Robertson previously served as Chief Legal and Administrative Officer at Lexeo and brings extensive experience from her previous roles at Pfizer, where she provided counsel on commercialization, clinical development, and intellectual property matters. With a background in complex commercial litigation, Ms. Robertson has played a crucial role in supporting Lexeo’s growth and strategic direction.
